Skip Navigation
Department of Health and Human Services
Slide Tray
0 slides

Return to Slide Library


Add Presentation to Slide Tray Presentation:

Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care

Slide: 1 of 36

Comparative Effectiveness of Recombinant Factor VIIa for Off-Label Uses vs. Usual Care in the Hospital Setting

This slide set is based on the research presented in a comparative effectiveness review (CER) , Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care, that was developed by the Stanford-UCSF Evidence-based Practice Center for the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0017) and is available online at The findings and conclusions in this document are those of the author(s), who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information presented here is intended to help health care decisionmakers—clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This information is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, that is, in the context of available resources and circumstances presented by individual patients.

CERs represent systematic reviews of the literature and usually compare two or more types of treatments, such as different drugs, devices, or procedures, for the same disease. The talk will cover data collected from the Perspective Comparative Database of Premier, Inc., in Charlotte, NC (2000 to 2008), as well as the current evidence from 10 electronic databases, grey literature, trial registries, and reference lists that were searched. Finally, the manufacturer’s web site and files supplied by the manufacturer of rFVIIa (Novo Nordisk) were reviewed, bibliographies of identified meta-analyses and systematic reviews were searched, and experts in the field were contacted to uncover studies not already identified by these searches. The methods used to develop this CER followed version 1.0 of the Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews published by AHRQ (draft available at: